

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

Wai C. Wong, et al.
Application No: 09/855,597
Filed: May 15, 2001
Page 2

has been previously been established. With a one-month extension of time, a response is now due on September 5, 2003. Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

In the Claims

Please amend the claims by replacing all prior versions of the claims pursuant to 37 C.F.R. §1.121 as modified by 68 Fed. Reg. 38611 (June 30, 2003) as follows:


DI 1-12. (Previously Cancelled)

13. (Currently Cancelled)

14. (Currently Amended) The compound of claim ~~13~~ 59, wherein the compound comprises the (-) enantiomer.

15. (Currently Amended) The compound of claim ~~13~~ 59, wherein the compound comprises the (+) enantiomer.

16. (Currently Amended) The compound of claim ~~13~~ 59 having the structure:



17-19. (Currently Cancelled)

20. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim ~~13~~ 59 and a pharmaceutically acceptable carrier.
21. (Original) The pharmaceutical composition of claim 20 wherein the amount of the compound is an amount from about 0.01 mg to about 500 mg.
22. (Original) The pharmaceutical composition of claim 21 wherein the amount of the compound is from about 0.1 mg to about 60 mg.
23. (Original) The pharmaceutical composition of claim 22 wherein the amount of the compound is from about 1 mg to about 20 mg.
24. (Previously Cancelled)
25. (Original) The pharmaceutical composition of claim 20, wherein the carrier is a solid and the composition is a tablet.
26. (Previously Cancelled)
27. (Original) The pharmaceutical composition of claim 20, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign

prostatic hyperplasia.

- D'
28. (Currently Amended) A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim ~~13~~ 59 effective to treat benign prostatic hyperplasia.
29. (Currently Amended) A The method of claim 28, wherein the compound additionally does not cause a fall in blood pressure at dosages effective to alleviate benign prostatic hyperplasia.
30. (Original) The method of claim 29, wherein the compound effects treatment of benign prostatic hyperplasia by relaxing lower urinary tract tissue.
31. (Original) The method of claim 30, wherein lower urinary tract tissue is prostatic smooth muscle.
- 32-40. (Previously Cancelled)
41. (Currently Amended) A method of treating a subject suffering from benign prostatic hyperplasia which comprises administering to the subject an amount of the compound of claim ~~13~~ 59 in combination with a 5 alpha-reductase inhibitor effective to treat benign prostatic hyperplasia.
42. (Original) The method of claim 41, wherein the 5-alpha

reductase inhibitor is finasteride.


D 43-44. (Previously Cancelled)

45. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim ~~13~~ 59 in combination with a therapeutically effective amount of finasteride and a pharmaceutically acceptable carrier.

46-52. (Previously Cancelled)


53-58. (Currently Cancelled)

59. (New) A compound having the structure:



wherein A is

D'



wherein each of Y_1, Y_2, Y_3, Y_4 and Y_5 is independently -H; straight chained or branched C_1 - C_7 alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C_2 - C_7 alkenyl or alkynyl; C_3 - C_7 cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -F, -Cl, -Br, or -I; - NO_2 ; - N_3 ; -CN; - OR_4 , - $OCOR_4$, - COR_4 , - $CONHR_4$, - $CON(R_4)_2$, or - $COOR_4$; or any two of Y_1, Y_2, Y_3, Y_4 and Y_5 present on adjacent carbon atoms can constitute a methylenedioxy group;

wherein X is S; O; or NR_4 ;

wherein B is -H; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; alkoxy or thioalkyl; straight chained or branched C₂-C₇ alkenyl; -SCH₂C₆H₄OR₄, - (CH₂)_nC₆H₅, -CH₂X(CH₂)_nNHR₄; -(CH₂)_nNHR₄ or -OR₄ with the proviso that B cannot be -OH or -OCH₃;


wherein R₁ is -H; -NO₂; -CN; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; -N(R₄)₂; -OR₄; -(CH₂)_pOR₄; -COR₄; -CO₂R₄; or -CON(R₄)₂;

wherein R₂ is -H; straight chained or branched C₁-C₇ alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl; C₃-C₁₀ cycloalkyl-C₁-C₁₀-alkyl, C₃-C₁₀ cycloalkyl-C₁-C₁₀-monofluoroalkyl or C₃-C₁₀ cycloalkyl-C₁-C₁₀-polyfluoroalkyl; -CN; -CH₂XR₄, -CH₂X(CH₂)_pNHR₄, -(CH₂)_nNHR₄, -CH₂X(CH₂)_pN(R₄)₂, or -CH₂X(CH₂)_pNHCXR₇; or -OR₄;

wherein each p is independently an integer from 1 to 7;

wherein each n is independently an integer from 0 to 5;

wherein R₃ is



wherein Z is C₂-C₇ alkenyl or alkynyl; CH₂; O; CO; CO₂ CONR₄; S; SO; SO₂; or NR₄;

wherein each V is independently O; S; CH₂; CR₅R₇; C(R₇)₂; or NR₇;

wherein each m is independently an integer from 0 to 3;

wherein each R is independently -H; -F; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; -N(R₄)₂; -NO₂; -CN; -CO₂R₄; or -OR₄;

wherein each R₄ is independently -H; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;

wherein R₅ is aryl or heteroaryl substituted with one or more F; Cl; Br; I; COR₃; CO₂R₃; -CON(R₃)₂; CN; -NO₂; N(R₃)₂; -OR₃; -SR₃; (CH₂)_oOR₃; (CH₂)_oSR₃; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C₂-C₇ alkenyl; C₂-C₇ alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl, or cycloalkenyl;


wherein each R₆ is independently -H; straight chained or branched C₁-C₇ alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, monofluoroalkyl or polyfluoroalkyl; straight chained or branched C₂-C₇ alkenyl or alkynyl; C₃-C₇ cycloalkyl,

monofluorocycloalkyl, polyfluorocycloalkyl or cycloalkenyl;
or -OR₄;


wherein R₇ is aryl or heteroaryl substituted with one or more F; Cl; Br; I; COR₄; CO₂R₄; -CON(R₄)₂; CN; -NO₂; -N(R₄)₂; -OR₄; -SR₄; (CH₂)_oOR₄; (CH₂)_oSR₄; straight chained or branched C₁-C₇ alkyl, monofluoroalkyl, polyfluoroalkyl, aminoalkyl, or carboxamidoalkyl; straight chained or branched C₂-C₇ alkenyl; C₂-C₇ alkynyl; C₃-C₇ cycloalkyl, monofluorocycloalkyl, polyfluorocycloalkyl, or cycloalkenyl;

or a pharmaceutically acceptable salt thereof.


60. (New) The compound of claim 59 having the structure




61. (New) A compound selected from the group consisting of:




62. (New) A compound having the structure:




63. (New) A compound having the structure:




64. (New) A compound having the structure:



65. (New) A compound having the structure:



66. (New) A compound having the structure:



67. (New) A compound having the structure:

